Octreotide, a somatostatin analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulating hormone threshold in polycystic ovary syndrome

Human Reproduction

Volumn 13, Issue 6, 1998, Pages 1465-1469

  Van der Meer, M ^a   De Boer, J A M ^a   Hompes, P G A ^a   Schoemaker, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FSH threshold; Gonadotrophins; Octreotide; Ovulation induction; Polycystic ovary syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION;

FALLOPIA;

EID: 0031861181     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/13.6.1465     Document Type: Article

References (24)

1. Adashi, E.Y., Resnick, C.E., Hurwitz, A. et al. (1991) Insulin-like growth factors: the ovarian connection. Hum. Reprod., 6, 1213-1219.
2. Chang, R.J., Nakamura, R.M., Judd, H.L. et al. (1983) Insulin resistance in non-obese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab., 57, 76-82.
3. Dunaif, A., Segal, K.R., Futterweit, W. et al. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165-1174.
4. Eden, J.A., Jones, J., Carter, G.D. et al. (1988) A comparison of follicular fluid levels of insulin-like growth factor-I in normal dominant and cohort follicles, polycystic and multicystic ovaries. Clin. Endocrinol. (Oxf), 29, 327-336.
5. Fulghesu, A.M., Lanzone, A., Andreani, C.L. et al. (1995) Effectiveness of a somarostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil. Steril., 64, 703-708.
6. Giudice, L.C. (1992) Insulin-like growth factors and ovarian follicular development. Endocr. Rev., 13, 641-669.
7. Homburg, R., Levy, T. and Ben-Rafael, Z. (1995) Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial. Hum. Reprod., 10, 2550-2553.
8. Katagiri, S., Moon, Y.S., Ho Yuen, B. (1997) A somatostatin analogue decreases embryonic loss following superovulation in rats by normalizing insulin-like growth factor-I action in the uterus. Hum. Reprod., 12, 671-676.
9. Katz, E., Ricciarelli, E. and Adashi, E.Y. (1993) The potential relevance of growth hormone to female reproductive physiology and pathophysiology. Fertil. Steril., 59, 8-34.
10. Kesteren, P. van, Lips, P., Deville, W. et al. (1996). The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-I in transsexuals. J. Clin. Endocrinol. Metab., 81, 2227-2232.
11. Kuhn, J.M., Basin, C., Mollard, M. et al. (1992) Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur. J. Clin. Invest., 22, 793-799.
12. Marbach, P., Briner, U., Lemaire, M. et al. (1992) From somatostatin to Sandostatin®: pharmacodynamics and pharmacokinetics. Metabolism, 41, 7-10.
13. Minakami, H., Abe, N., Izumi, A. et al. (1988) Serum luteinizing hormone profile during the menstrual cycle in polycystic ovarian syndrome. Fertil. Steril, 50, 990-992.
14. Monget, P. and Martin, G.B. (1997) Involvement of insulin-like growth factors in the interactions between nutrition and reproduction in female mammals. Hum. Reprod., 12, 33-52.
15. Morris, R.S., Carmina, E., Vijod, M.A. et al. (1995) Alterations in the sensitivity of serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. Fertil. Steril, 63, 742-746.
16. Pawelczyk, L.A., Duleba, A.J., Moon, Y.S. et al. (1993) Sandostatin has no direct effect on ovarian steroidogenesis in vitro. Hum. Reprod., 8, 364-368.
17. Prelevic, G.M., Wurzburger, M.I., Balint-Peric, L. et al. (1990) Inhibitory effect of sandostatin and ovarian steroids in polycystic ovary syndrome. Lancet, 336, 900-903.
18. Prelevic, G.M., Wurzburger, M.I. and Balint-Peric, L. (1992a) The effect of somatostatin analog octreotide (Sandostatin®) on luteinizing hormone and ovarian steroids in insulin-dependent diabetic women without residual insulin secretion. Gynecol. Endocrinol., 6, 259-263.
19. Prelevic, G.M., Wurzburger, M.I., Balint-Peric, P. et al. (1992b) Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries. Horm. Res., 37, 125-131.
20. Prelevic, G.M., Ginsburg, J., Maletic, D. et al. (1995) The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Hum. Reprod., 10, 28-32.
21. Rabinovici, J., Dandekar, P., Angle, M.J. et al. (1990) Insulin-like growth factor I (IGF-I) levels in follicular fluid from preovulatory follicles: correlation with serum IGF-I levels. Fertil. Steril., 54, 428-433.
22. van der Meer, M., Hompes, P.G.A., Scheele, F. et al. (1994) Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome. Hum. Reprod., 9, 1612-1617.
23. Volpe, A., Artini, P.G., Barreca, A. et al. (1992) Effects of growth hormone administration in addition to gonadotrophins in normally ovulating women and polycystic ovary syndrome. Hum. Reprod., 10, 1347-1352.
24. White, D.M., Polson, D.W., Kiddy, D. et al. (1996) Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab., 81, 3821-3824.